Table of Contents
In 2013, healthcare moved towards access, transparency, investments, and spending. In 2014, Frost & Sullivan anticipates new launches to occur across the life sciences spectrum, from preventive medicine to treating complex diseases. This market insight touches upon major events that occurred in 2013 and how 2014 is expected to shape up, including future investments, regulatory changes, and new launches. Key companies to watch are highlighted, and strategic recommendations are provided.
The pharmaceutical/biotechnology industry is continuing to move away from the blockbuster
model approach and towards the treatment of orphan diseases and personalized medicine.
Continued growth in personalized medicine and companion diagnostics will move beyond
oncology and into areas such as virology, central nervous system, and cardiology.
While the number of new molecular entities (NMEs) continues to decline, the life sciences
industry has made great progress in treating complex conditions and providing greater ease
of use for patients (e.g., oral medicines for complex conditions such as hepatitis C and
The industry is seeing increasing speed and intensity of product competition in the areas of
generics and biosimilars, including the recent European launch of biosimilar monoclonal
It is becoming the norm worldwide for payments and reimbursements to be tied to quality of
Pharmaceutical companies continue to move beyond the pill. Big pharma companies are
looking to adopt alternative business models beyond prescription treatments to support the
entire continuum of care such as disease prevention and patient monitoring.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential Summary Immunology is a large therapy area characterized by disorders of ...
Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation Summary Head and neck cancer (HNC) is the sixth most common malignancy worldwide, ...
“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...